JP2022517329A5 - - Google Patents

Info

Publication number
JP2022517329A5
JP2022517329A5 JP2021539522A JP2021539522A JP2022517329A5 JP 2022517329 A5 JP2022517329 A5 JP 2022517329A5 JP 2021539522 A JP2021539522 A JP 2021539522A JP 2021539522 A JP2021539522 A JP 2021539522A JP 2022517329 A5 JP2022517329 A5 JP 2022517329A5
Authority
JP
Japan
Prior art keywords
labyrintin
isolated anti
antibody
construct according
labyrinthin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012613 external-priority patent/WO2020146413A1/en
Publication of JP2022517329A publication Critical patent/JP2022517329A/ja
Publication of JP2022517329A5 publication Critical patent/JP2022517329A5/ja
Priority to JP2024218292A priority Critical patent/JP2025060688A/ja
Pending legal-status Critical Current

Links

JP2021539522A 2019-01-08 2020-01-07 ラビリンチン又はその一部を標的とする構築物及びその使用 Pending JP2022517329A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218292A JP2025060688A (ja) 2019-01-08 2024-12-13 ラビリンチン又はその一部を標的とする構築物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789871P 2019-01-08 2019-01-08
US62/789,871 2019-01-08
PCT/US2020/012613 WO2020146413A1 (en) 2019-01-08 2020-01-07 Constructs targeting labyrinthin or a portion thereof and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218292A Division JP2025060688A (ja) 2019-01-08 2024-12-13 ラビリンチン又はその一部を標的とする構築物及びその使用

Publications (2)

Publication Number Publication Date
JP2022517329A JP2022517329A (ja) 2022-03-08
JP2022517329A5 true JP2022517329A5 (https=) 2023-01-19

Family

ID=71520309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539522A Pending JP2022517329A (ja) 2019-01-08 2020-01-07 ラビリンチン又はその一部を標的とする構築物及びその使用
JP2024218292A Pending JP2025060688A (ja) 2019-01-08 2024-12-13 ラビリンチン又はその一部を標的とする構築物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218292A Pending JP2025060688A (ja) 2019-01-08 2024-12-13 ラビリンチン又はその一部を標的とする構築物及びその使用

Country Status (11)

Country Link
US (1) US20220089719A1 (https=)
EP (1) EP3908612A4 (https=)
JP (2) JP2022517329A (https=)
KR (1) KR20210137997A (https=)
CN (1) CN113993892A (https=)
AU (1) AU2020206329A1 (https=)
CA (1) CA3126063A1 (https=)
IL (1) IL284638A (https=)
MX (1) MX2021008205A (https=)
TW (1) TW202043270A (https=)
WO (1) WO2020146413A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
EP1789447B1 (en) * 2004-08-16 2012-04-25 Immune Disease Institute, Inc. Method of delivering rna interference and uses thereof
WO2011116014A2 (en) * 2010-03-15 2011-09-22 Mission Therapeutics, Inc. Humanized antibodies to labyrinthin and uses thereof
US20110230433A1 (en) * 2010-03-16 2011-09-22 University Of Washington Compositions and methods for treatment of cancer
JP6117515B2 (ja) * 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
WO2016134284A1 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
WO2016161390A1 (en) * 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
CA3021634A1 (en) * 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
AU2018257894A1 (en) * 2017-04-24 2019-10-31 Kite Pharma, Inc. Humanized antigen-binding domains against CD19 and methods of use
WO2019217913A1 (en) * 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof

Similar Documents

Publication Publication Date Title
CN112646031B (zh) 抗4-1bb纳米抗体及其用途
JP2019116474A5 (https=)
JP2020525032A5 (https=)
JP2018512145A5 (https=)
JP2019505564A5 (https=)
JP2023508174A5 (https=)
JP2022548777A5 (https=)
CN112745392B (zh) 抗pd-l1/cd47双特异性抗体及其用途
JP2019511201A5 (https=)
JP2022545655A5 (https=)
JP2022513050A5 (https=)
CN110036028A (zh) 抗il1-rap抗体
JP2023524102A5 (https=)
JP2024001073A5 (https=)
JP2020534012A5 (https=)
JP2019505166A5 (https=)
JP2019504615A5 (https=)
JP2023508173A5 (https=)
JP2023502990A5 (https=)
WO2021047386A1 (zh) 靶向caix抗原的纳米抗体及其应用
JP2024515560A5 (https=)
CN117083301A (zh) 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
JP2023536631A5 (https=)
US11306151B2 (en) Anti-TIP-1 antibodies and uses thereof
JP2024514830A5 (https=)